Authors: Sausville, EA Arbuck, SG Messmann, R Headlee, D Bauer, KS Lush, RM Murgo, A Figg, WD Lahusen, T Jaken, S Jing, XX Roberge, M Fuse, E Kuwabara, T Senderowicz, AM

Citation: Ea. Sausville et al., Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms, J CL ONCOL, 19(8), 2001, pp. 2319-2333

Authors: Messmann, RA Vitetta, ES Headlee, D Senderowicz, AM Figg, WD Schindler, J Michiel, DF Creekmore, S Steinberg, SM Kohler, D Jaffe, ES Stetler-Stevenson, M Chen, HC Ghetie, V Sausville, EA

Citation: Ra. Messmann et al., A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma, CLIN CANC R, 6(4), 2000, pp. 1302-1313

Authors: Bergan, RC Reed, E Myers, CE Headlee, D Brawley, O Cho, HK Figg, WD Tompkins, A Linehan, WM Kohler, D Steinberg, SM Blagosklonny, MV

Citation: Rc. Bergan et al., A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer, CLIN CANC R, 5(9), 1999, pp. 2366-2373

Authors: Sausville, EA Zaharevitz, D Gussio, R Meijer, L Louarn-Leost, M Kunick, C Schultz, R Lahusen, T Headlee, D Stinson, S Arbuck, SG Senderowicz, A

Citation: Ea. Sausville et al., Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target, PHARM THERA, 82(2-3), 1999, pp. 285-292

Authors: Senderowicz, AM Reid, R Headlee, D Abornathy, T Horti, J Lush, RM Reed, E Figg, WD Sausville, EA

Citation: Am. Senderowicz et al., A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer, UROL INTERN, 63(2), 1999, pp. 120-125